AMBAR

Alzheimer's disease is a 21st century epidemic that currently affects more than 35 million people worldwide, with this number estimated to rise to 82 million by 2030. The fifth leading cause of death globally and the most common cause of dementia, Alzheimer's costs society upwards of $818 billion a year; yet despite significant research and investment, it remains an incurable disease.

Grifols' research into Alzheimer's began with a small clinical study into the potential of plasma exchange with albumin to slow the progression of the disease in mild and moderate AD patients.

More than a decade later, this research has become a phase IIb/III clinical trial: AMBAR, Alzheimer Management by Albumin Replacement.

The AMBAR clinical trial has been carried out in 41 hospitals across the U.S. and Spain, in collaboration with some of the world's leading Alzheimer's research centers and organizations.

In October 2018 we presented primary outcomes of the AMBAR study (phase IIb/III) at the Clinical Trials on Alzheimer's Disease (CTAD) congress, hold in Barcelona. In 2019 we plan to present new results at other global congresses including the Alzheimer's Association International Conference (AAIC) in July and this year's edition of the CTAD, which will be held in December.

+ 35 million
people world-wide suffer from Alzheimer's disease (AD)

14 years
of research on AD

+ €150 million
invested in AD research since 2004

+ 35 million
people world-wide suffer from Alzheimer's disease (AD)

14 years
of research on AD

+ €150 million
invested in AD research since 2004